Arena Pharmaceuticals (ARNA -3.6%) says an FDA advisory committee will meet in the second...


Arena Pharmaceuticals (ARNA -3.6%) says an FDA advisory committee will meet in the second quarter to discuss the company's resubmitted application for its weight-loss drug lorcaserin. There are concerns by many analysts that lorcaserin may not be as effective as other drugs being developed.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs